Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

753
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
753
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.0K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.0K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

626
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
626

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocarditis Due to <i>Scedosporium</i> spp and <i>Lomentospora prolificans</i>: Case Series and Literature Review.

Open forum infectious diseases·2026
Same author

Non-invasive management of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

American journal of respiratory and critical care medicine·2026
Same author

Direct carbapenemase typing from disc diffusion antibiograms with MALCA (MAchine Learning CArbapenemase).

Nature communications·2026
Same author

Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis.

Nature communications·2026
Same author

Occupational Transmission of Extensively Drug-Resistant Tuberculosis, France.

Emerging infectious diseases·2026
Same author

Evaluation of the BL-RED test and comparison with the β-LACTA test for rapid detection of resistance to third-generation cephalosporins in <i>Enterobacterales</i> on early culture of positive blood cultures.

Microbiology spectrum·2026

Related Experiment Video

Updated: Mar 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Rifabutin: where do we stand in 2016?

Yoann Crabol1, Emilie Catherinot2, Nicolas Veziris3

  • 1APHP-Hôpital Necker-Enfants malades, Service de Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France.

The Journal of Antimicrobial Chemotherapy
|March 25, 2016
PubMed
Summary
This summary is machine-generated.

Rifabutin, a WHO Essential Medicine, shows comparable efficacy to rifampicin for mycobacterial diseases with better liver safety profiles. Its use in rifampicin-resistant tuberculosis remains controversial, requiring further research.

More Related Videos

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

1.6K
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

82.2K

Related Experiment Videos

Last Updated: Mar 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

1.6K
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

82.2K

Area of Science:

  • Pharmacology and Infectious Diseases

Background:

  • Rifabutin, a rifamycin derivative, is a WHO Essential Medicine with a narrower indication range than rifampicin, despite being available for 24 years.
  • Understanding rifabutin's properties is crucial for expanding its clinical applications.

Purpose of the Study:

  • To comprehensively review rifabutin's pharmacokinetics, pharmacodynamics, antimicrobial activity, resistance patterns, and side effects compared to rifampicin.
  • To elucidate the reasons behind rifabutin's limited indications.

Main Methods:

  • A comprehensive review of existing experimental and clinical studies on rifabutin.
  • Comparative analysis of rifabutin and rifampicin based on pharmacokinetic, pharmacodynamic, and clinical data.

Main Results:

  • Rifabutin demonstrates equivalent or superior activity and acceptable tolerance compared to rifampicin in treating tuberculosis and non-tuberculous mycobacterial diseases.
  • Rifabutin offers clinical advantages in patients with AIDS, transplant recipients, or those experiencing rifampicin intolerance due to lower liver enzyme induction.
  • Rifabutin's role in treating rifampicin-resistant, but rifabutin-susceptible, Mycobacterium tuberculosis is debated; its lower AUC is offset by higher intracellular penetration and lower MICs.

Conclusions:

  • Rifabutin is a viable alternative to rifampicin for mycobacterial infections, particularly when liver safety is a concern.
  • Further clinical studies are needed to explore rifabutin's efficacy in non-mycobacterial infections.